Fri, Dec 26, 2014, 8:54 AM EST - U.S. Markets open in 36 mins.

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • posgost67 posgost67 Jul 11, 2013 4:22 PM Flag

    You guys realize...

    That the trial results were positive for CF? Given there are not many options for drug resistant pseudomonas, and most CF patients are on long courses of tobi or colistin or amikacin (poor absorption/penetration compared to arikace), they need another option for inhaled antibiotic therapy. It won't be first line, but you won't keep giving tobi or colistin to a patient whose pseudomonas has become resistant to those drugs. Arikace would be a better option than systemic antibiotics, which are reserved for active infections or patients with really poor lung function that can't tolerate another infection (pre-transplant). Some of you really are like the world is ending (longs I'm talking about, not even shorts). Sheesh

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "It won't be first line, but you won't keep giving tobi or colistin to a patient whose pseudomonas has become resistant to those drugs."

      I believe we've now got to the bit where you explain why Arikace will not be first line.

      As a doctor and a scientist I know it's second nature for you to avoid speculation - and to only present as fact information you know to be indisputable.

      My assumption that Arikace will be the central therapy in the antibiotic regimen by virtue of the fact that no other inhaled antibiotic has generated data which even hints at improving lung function for longer than a couple of phases of therapy is clearly flawed. I look forward to a clear explanation of the factor I've overlooked.

 
INSM
15.29+0.15(+0.99%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Gilead Sciences Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Spectrum Pharmaceuticals, Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST